表紙
市場調査レポート

Herantis Pharma plc.の製品パイプライン分析

Herantis Pharma Plc - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 321997
出版日 ページ情報 英文 28 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.02円で換算しております。
Back to Top
Herantis Pharma plc.の製品パイプライン分析 Herantis Pharma Plc - Product Pipeline Review - 2015
出版日: 2015年10月30日 ページ情報: 英文 28 Pages
概要

Herantis Pharma plc.はフィンランドに本社を置くバイオ製薬企業です。アンメット医療ニーズに対応する新薬の開発に特化しており、開発対象はドライアイ、パーキンソン病、続発性リンパ浮腫、アトピー性皮膚炎、筋萎縮性側索硬化症(ALS)治療薬といった多様な分野にわたっています。

当レポートでは、Herantis Pharma plc.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Herantis Pharma plc.の基本情報

  • Herantis Pharma plc.の概要
  • 主要情報
  • 企業情報

Herantis Pharma plc.:R&Dの概要

  • 主な治療範囲

Herantis Pharma plc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Herantis Pharma plc.:パイプライン製品の概況

  • 臨床段階にあるパイプライン製品
    • 第2相の製品/併用療法モダリティ
    • 第1相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ

Herantis Pharma plc.:薬剤プロファイル

  • Small Molecule for Immunology, Ophthalmology, Oncology and Dermatology
  • HER-902
  • LX-1101
  • Recombinant Protein for Amyotrophic Lateral Sclerosis

Herantis Pharma plc.:パイプライン分析

  • 標的
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Herantis Pharma plc.:最新のパイプライン情報

Herantis Pharma plc.:開発休止中のプロジェクト

Herantis Pharma plc.:本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07725CDB

Summary

Global Markets Direct's, 'Herantis Pharma Plc - Product Pipeline Review - 2015', provides an overview of the Herantis Pharma Plc's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Herantis Pharma Plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Herantis Pharma Plc including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Herantis Pharma Plc's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Herantis Pharma Plc's pipeline products

Reasons to buy

  • Evaluate Herantis Pharma Plc's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Herantis Pharma Plc in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Herantis Pharma Plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Herantis Pharma Plc and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Herantis Pharma Plc
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Herantis Pharma Plc and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Herantis Pharma Plc Snapshot
    • Herantis Pharma Plc Overview
    • Key Information
    • Key Facts
  • Herantis Pharma Plc - Research and Development Overview
    • Key Therapeutic Areas
  • Herantis Pharma Plc - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Herantis Pharma Plc - Pipeline Products Glance
    • Herantis Pharma Plc - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Herantis Pharma Plc - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Herantis Pharma Plc - Drug Profiles
    • Cis-Urocanic Acid
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HER-902
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LX-1101
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protien for Amyotrophic Lateral Sclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protien for Alzheimer's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Herantis Pharma Plc - Pipeline Analysis
    • Herantis Pharma Plc - Pipeline Products by Target
    • Herantis Pharma Plc - Pipeline Products by Route of Administration
    • Herantis Pharma Plc - Pipeline Products by Molecule Type
    • Herantis Pharma Plc - Pipeline Products by Mechanism of Action
  • Herantis Pharma Plc - Recent Pipeline Updates
  • Herantis Pharma Plc - Dormant Projects
  • Herantis Pharma Plc - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Herantis Pharma Plc, Key Information
  • Herantis Pharma Plc, Key Facts
  • Herantis Pharma Plc - Pipeline by Indication, 2015
  • Herantis Pharma Plc - Pipeline by Stage of Development, 2015
  • Herantis Pharma Plc - Monotherapy Products in Pipeline, 2015
  • Herantis Pharma Plc - Phase II, 2015
  • Herantis Pharma Plc - Preclinical, 2015
  • Herantis Pharma Plc - Pipeline by Target, 2015
  • Herantis Pharma Plc - Pipeline by Route of Administration, 2015
  • Herantis Pharma Plc - Pipeline by Molecule Type, 2015
  • Herantis Pharma Plc - Pipeline Products by Mechanism of Action, 2015
  • Herantis Pharma Plc - Recent Pipeline Updates, 2015
  • Herantis Pharma Plc - Dormant Developmental Projects,2015
  • Herantis Pharma Plc, Other Locations

List of Figures

  • Herantis Pharma Plc - Pipeline by Top 10 Indication, 2015
  • Herantis Pharma Plc - Pipeline by Stage of Development, 2015
  • Herantis Pharma Plc - Monotherapy Products in Pipeline, 2015
  • Herantis Pharma Plc - Pipeline by Top 10 Route of Administration, 2015
  • Herantis Pharma Plc - Pipeline by Top 10 Molecule Type, 2015
Back to Top